New cocktail therapy aims to shrink untreatable liver tumors
NCT ID NCT07543510
First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy) along with targeted chemotherapy delivered directly to the liver via a catheter. The goal is to improve tumor shrinkage in 38 patients with advanced liver cancer that cannot be surgically removed. The study will measure how many patients respond and how long they live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab and atezolizumab (immunotherapy and anti-angiogenic drugs) combined with chemotherapy delivered directly to the liver
What this could lead to
If successful, this combination could offer a more effective first-line treatment for people with advanced liver cancer that cannot be removed surgically.
What could go wrong
This is a small, early-phase trial with only 38 participants and no comparison group, so results may not apply broadly. The combination also carries risks like bleeding, liver damage, and immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.